Latest news and articles about long COVID from NEX English
New reports indicate that the cost of long COVID could amount to <strong>€116 billion</strong> annually in OECD countries, reflecting the ongoing impact of the pandemic on the global economy. These costs are equivalent to the annual health budgets of countries like the <strong>Netherlands</strong> and <strong>Spain</strong>.
A recent study from the Karolinska Institute in Sweden indicates that individuals suffering from long COVID face an increased risk of cardiovascular diseases, highlighting the complications of this illness years after infection.
Researchers have revealed that the drug fluvoxamine, used as an antidepressant, significantly improves the quality of life for adults suffering from long COVID symptoms. This low-cost medication offers new hope for many patients.
A new study reveals that the drug fluvoxamine, typically used as an antidepressant, significantly improves the quality of life for adults suffering from long-term COVID. Conducted in Brazil, the clinical trial involved 399 participants experiencing fatigue for at least 90 days post-infection.